Study of BEMAâ¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Information source: BioDelivery Sciences International
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain; Cancer
Intervention: BEMAâ¢ Fentanyl (Drug)
Phase: Phase 3
Sponsored by: BioDelivery Sciences International
Official(s) and/or principal investigator(s):
Andrew Finn, PharmD, Study Chair, Affiliation: BioDelivery Sciences International
The purpose of this study is to evaluate the efficacy of BEMA fentanyl at any dose in the
management of breakthrough pain in cancer subjects on background opioid therapy. The
standard of care for these breakthrough pain episodes is a rapid onset, short acting
analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are
routinely used, but because of slow and variable oral absorption, the pain control is not the
best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used
successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge
of fentanyl on a stick and is administered by continuously swabbing the interior of the
subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal
route of administration avoids the delay and variability associated with oral absorption.
BioDelivery Sciences International, Inc. (BDSI) has developed BEMA (BioErodible MucoAdhesive)
fentanyl, an alternative product to OTFC that does not require the subject to continuously
paint the inside of the mouth with the dosage form. The BDSI product is a small disc that is
placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the disc
readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of
the disc are water soluble, so the entire dosage form dissolves within 30 minutes of
Official title: A Double-Blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Safety/Efficacy Study
Primary outcome: Summary of Pain Intensity Differences
Minimum age: 18 Years.
Maximum age: N/A.
- Male or non-pregnant and non-lactating female. A female of child-bearing potential is
eligible to participate in this study if she is using an acceptable method of birth
- 18 years or older
- Patient must have pain associated with cancer or cancer treatment.
- Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000
mg/day of oral morphine or 50 - 300 Âµg/hr of transdermal fentanyl (e. g. oxycodone 30
mg, methadone 20 mg, and hydromorphone 7. 5 mg).
- Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional
opioids for pain control
- At least partial relief of breakthrough pain by use of opioid therapy
- Subject must be able to self-administer the study medication correctly.
- Subject must be willing and able to complete the electronic diary card with each pain
- Signed consent must be obtained at screening prior to any procedures being performed.
- Psychiatric/cognitive or neurological impairment that would limit the subject's
ability to understand or complete the diary
- Cardiopulmonary disease that, in the opinion of the investigator, would significantly
increase the risk of respiratory depression
- Recent history or current evidence of alcohol or other drug substance (licit or
- Rapidly escalating pain that the investigator believes may require an increase in the
dosage of background pain medication during the study
- Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate
mucositis are permitted and must be instructed to not apply the BEMA disc at a site of
- Strontium 89 therapy within the previous 6 months
- Any other therapy prior to the study that the investigator considers could alter pain
or the response to pain medication.
- Use of an investigational drug within 4 weeks preceding this study
- History of hypersensitivity or intolerance to fentanyl
- Regularly more than 4 episodes per day
- ECOG performance status of 4 or 5
- Subject is pregnant, actively trying to become pregnant, breast feeding or not using
adequate contraceptive measures
Locations and Contacts
PPD Development, Wilmington, North Carolina 28412, United States
Starting date: February 2006
Ending date: April 2007
Last updated: January 16, 2008